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Improvement of quality of life and survival of cancer patients will be greatly enhanced by the development of highly eﬀective drugs
to selectively kill malignant cells. Artemisinin and its analogs are naturally occurring antimalarials which have shown potent anti-
canceractivity.Inprimarycancerculturesandcelllines,theirantitumoractionswerebyinhibitingcancerproliferation,metastasis,
and angiogenesis. In xenograft models, exposure to artemisinins substantially reduces tumor volume and progression. However,
the rationale for the use of artemisinins in anticancer therapy must be addressed by a greater understanding of the underlying
mechanisms involved in their cytotoxic eﬀects. The primary targets for artemisinin and the chemical base for its preferential eﬀects
on heterologous tumor cells need yet to be elucidated. The aim of this paper is to provide an overview of the recent advances and
new development of this class of drugs as potential anticancer agents.
1.Introduction
Cancer remains as a life-threatening disease and a leading
cause of death as its control has been diﬃcult. Although, a
range of conventional therapies based on chemotherapy, sur-
gery, and radiotherapy are available, these approaches are in
many cases of limited eﬃcacy [1]. Moreover, current anti-
cancer regimens are frequently associated with signiﬁcant
levels of toxicity and the emergence of drug resistance. One
major challenge to relieve cancer burden is to develop highly
eﬀective drugs with speciﬁcity on cancers but little or no side
eﬀects on normal mammalian cells.
Many research projects have been focused on developing
new chemotherapies either by exploring the anticancer abil-
ity of novel compounds or by assessing drugs conventionally
used in other clinical diseases. Natural products have been
found to be a relevant source of novel and potent bioactive
compounds with minimal side eﬀects in vivo. Plant deriva-
tives have been known to be eﬀective against a range of di-
seases with broad antimicrobial activity, and some have also
exhibited signiﬁcant antitumor activity. One of the promis-
ing compounds is artemisinin, a naturally occurring anti-
malarial with anticancer properties [2]. Artemisinin and its
derivatives, which are commonly used in malaria therapy,
have also potent anticancer activity in the nano- to-micro-
molar range in sensitive and drug- or radiation-resistant cell
lines [3–5]. Importantly, artemisinin is one of the very few
drugs that have been widely used as antimalarials but has no
signiﬁcant side eﬀects [6] or clinical resistance, although tol-
erance has been reported [7]. Recently, growing amount of
research has focused on the mechanisms underlying the ac-
tion and response to artemisinin-like drugs.
In this review, we will revisit some of the key issues in the
development of artemisinin and its analogs as anticancer
agents to better understand the mechanisms of their antitu-
mor eﬀects from the insights of new gained knowledge. By
considering the beneﬁts, limitations, and current and future
development of artemisinins, we can then identify emerging2 Journal of Biomedicine and Biotechnology
questionsandaddressfutureresearchneedsinthispromising
ﬁeld of cancer drug discovery.
2. ArtemisininandIts Derivatives
Artemisinin is a sesquiterpene lactone with a 1,2,4-tiroxane
ring system (Figure 1). This endoperoxide compound is ex-
tractedfromtheChineseherbqinghaosu(Artemisiaannuaor
annual wormwood) which was used for treating fevers for
over two millennia [8]. Despite its eﬃcacy, the prototype
drug, artemisinin, has pharmacokinetic limitations. Natu-
rally, artemisinin has low solubility in water or oil, poor
bioavailability, and a short half-life in vivo (∼2.5h) [9, 10].
To overcome some of these problems, three generations
of artemisinin-like endoperoxides including semisynthetic
derivatives and fully synthetic compounds have been devel-
oped. So far, two generations of semisynthetic derivatives
of artemisinin such as artesunate, arteeter, artemether, and
artemisone have been eﬀectively used as antimalarials with
good clinical eﬃcacy and tolerability (Figure 1).
Semisynthetic artemisinins are obtained from dihydro-
artemisinin (DHA), the main active metabolite of artemi-
sinin [11, 12]. The ﬁrst generation of semisynthetic arte-
misininsincludesarteeterandartemether,thelipophilicarte-
misinins, whereas artesunate is the water soluble deriva-
tive [11, 12]. Artemisone, a second-generation artemisinin,
has shown improved pharmacokinetic properties including
longer half-life and lower toxicity [13]. So far, artesunate
is the derivative that is commonly used in the antimalarial
combination therapy.
Fully synthetic artemisinin derivatives have also been
designed by preserving the peroxide moiety which confers
potent drug activity. These compounds are easily synthesized
from simple starting materials, thus being currently under
intense development [14–17].
3. Antitumor Mechanismof
Action of Artemisinin
In the malaria parasite, the endoperoxide moiety of arte-
misinin has been shown to be pharmacologically important
and responsible of the antimalarial activity [18, 19]. The
endoperoxide bond is thought to be activated by reduced
heme (FPFeII) or ferrous iron (FeII) [20], leading to cyto-
toxic carbon-centered radicals which are highly potent alky-
lating agents [21]. Radicals may target essential parasite
macromolecules causing parasite’s death. However, the pre-
cise mechanism of action and primary target of artemisinin
remain under study. In Plasmodium, it has been postulated
that artemisinin may target organelles such as the mito-
chondrion,endoplasmicreticulum,andthedigestivevacuole
(reviewed in [22]). Some postulated molecular targets
include heme alkylation, protein alkylation, Ca2+ ATPase
(SERCA) inhibition, membrane damage, and loss of mito-
chondrial potential (reviewed in [22]). Despite the contin-
uous debate on artemisinin activation and speciﬁc targets,
supporting evidence points that heme or ferrous iron is re-
quired for potent activity [23]. This observation has been
substantiated in other systems. In Schistosomas, artemether
has an exquisite action against the tegument; this activity is
also enhanced by iron [24].
Interestingly, the potent anticancer action of artemisinin
can also be attributed to the endoperoxide bond (red square
in Figure 2) and shares the same parasitical chemical base.
Lack of the endoperoxide moiety does not completely abro-
gate anticancer activity [25] but signiﬁcantly reduces cyto-
toxicity to only ﬁftieth compared to those compounds
with the trioxane ring [26–28]. Residual anticancer activity
may be associated with an alternative peroxide-independent
mechanism [26]. In a general consensus, iron and heme or
heme-bound proteins have been involved in the bioreductive
activation of artemisinin [29–31]. In most of the systems,
preloading of cancer cells with iron or iron-saturated holo-
transferrin (diferric transferrin) triggers artemisinin cyto-
toxicity [32–35] with an increase in artemisinin activity up
to 100-fold in some cell lines [36]. Moreover, artemisinins
tagged to iron-carrying compounds exhibit greater activity
comparedwiththatofartemisininalone[37–39].Recently,it
was shown that chemical modulation using succinylacetone,
a heme synthesis inhibitor, decreases DHA cytotoxicity in
HL-60 (human promyelocytic leukemia cells) [35]. This was
consistent with previous studies showing that induction of
heme oxidase followed by downregulation of the heme syn-
thesisgenesmayalsoinhibitcytotoxicityofnovelartemisinin
dimersinthesamecancerline[40].Similarly,treatmentwith
desferroxamine(DFO),anironchelator,renderscompounds
inactive[41].Ironandhememetabolismmayhavearelevant
role in the selective antitumor activity of artemisinin. Con-
tinued proliferation and growth of malignant cells require
higher iron metabolism to achieve processes of cell survival
[35]. Therefore, cancer cells exhibit an increase in transferrin
receptors (TfR) which are responsible for the iron uptake
and regulation of intracellular concentrations. Levels of ex-
pression of TfR in cancer cells may vary depending on the
cell line. However, they diﬀer substantially from normal
cells leading to a high selectivity index of artemisinin and
its derivatives. Eﬀerth et al. reported that leukemia (CCRF-
CEM) and astrocytoma (U373) cells express TfR in 95% and
43% of the cell population, whereas normal monocytes only
account for approximately 1% [42, 43]. Blocking the TfR by
pretreatment with speciﬁc monoclonal antibodies abrogates
artemisinin activity [43].
It has been hypothesized that iron-activated artemisinin
induces damage by release of highly alkylating carbon-cen-
tered radicals and radical oxygen species (ROS) (Figure 2)
[28, 35]. Radicals may play a role in the cell alterations
reportedinartemisinin-treatedcancercellssuchasenhanced
apoptosis, arrest of growth, inhibition of angiogenesis, and
DNA damage (Figure 2). Several studies have also associated
artemisinin toxicity with impaired cytokinesis, enhanced
levelsofoxidativestress,inhibitionoftumorinvasion,migra-
tion, and metastasis (reviewed in [44]). ROS generation may
contribute with the selective action of artemisinin on can-
cer cells. Tumor cells have enhanced vulnerability to ROS
damage as they exhibit lower expression of antioxidant
enzymes such as superoxide dismutase, catalase, and glutha-
tione peroxidase compared to that of normal cells [45, 46].
Hence, increasing oxidative stress is a common anticancerJournal of Biomedicine and Biotechnology 3
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Figure 1: Chemical structure of artemisinin antimalarials (artemisinins) with anticancer activity. Artemisinin (1), dihydroartemisinin
(DHA) (2), artemether (3), artesunate (4), and artemisone (5).
mechanism of antitumor agents [47]. In addition, the selec-
tivity of artemisinin may be boosted by preferential targeting
of cancer biomarkers or overexpressed cancer genes and
proteins which are not detectable in normal diﬀerentiated
tissues [48].
3.1. Generation of ROS as a Primary Eﬀector of Cytotoxicity.
As in Plasmodium, the artemisinin molecular targets in can-
cer cells are debatable. Although artemisinin-induced alter-
ations in some tumor cells are consistent, it is not clear
if this toxicity resides in deﬁned molecular targets. Drug
concentrations required to have an eﬀect on cancer cells are
oftenhigherthanthoseinducingtoxicityinmalariaparasites.
Artemisinin, DHA, artesunate, and artemether exhibit 48h
IC50s (ﬁfty percent inhibitory concentration) up to 15nM in
malaria parasites [49, 50], whereas their anticancer activity
is cell-line dependent and IC50sﬂ u c t u a t eb e t w e e n0 . 5a n d
≥200μM[ 5]. The exquisite sensitivity of malaria parasites to
artemisininpointstothepresenceofspeciﬁcparasitictargets.
By contrast, in cancer cells, the artemisinin eﬀect seems to
be rather mediated by more general mechanisms through
generationof ROS. However, it has been suggestedthat ROS-
mediated damage may be triggered by an initiating event
in the vicinity of artemisinin activation [35]. Microscopy
analysesin artesunate-treatedcellshave shown earlyoncosis-
likemorphologicalchangesatsubcellularstructuresinwhich
ROS generation may be triggered [51].
Microarray analyses found that the action of artemisinin
seems to be modulated by the expression of oxidative stress
enzymes including catalase, thioredoxin reductase, superox-
ide dismutase and the glutathione S-transferase family [5,
52]. Artemisinin-sensitive cells have downregulated oxida-
tionenzymeswhereasoverexpressionofthesemoleculesren-
ders cancer cells less sensitive [5]. Direct evidence in the
HL-60 cell line has revealed that early and rapid generation
(1h) of ROS has been associated with apoptosis induction
and artemisinin-induced damage. Furthermore, IC50 has
been directly correlated with ROS levels [52]. Conversely,
the action of artemisinin in several experimental systems
has been reverted in presence of the antioxidant agents,
N-acetyl cysteine, and 1,2-dihydroxybenzene-3,5-disulfonic
acid(TIRON,anironscavenger),whichresultedinadelayin
cell death [40, 52, 53]. A recent study has demonstrated that
generation of ROS in artesunate-treated HeLa cells (16h)
occurring before cytotoxicity is being detected (48h) [35],
suggesting that this may be the starting event in artemisinin-
induced damage. The electron transfer chain (ETC) in the
mitochondrion has been proposed to play a role in the
generation of ROS, however substantial cytotoxicity is still
detected in HeLa cells devoid of ETC indicating that other
sources of ROS may be available in the cells [35]. Indeed,
emerging evidence has postulated that oxidative stress in
breast cancer cells is initially generated in the lysosome
as consequence of iron-activated artesunate in a process4 Journal of Biomedicine and Biotechnology
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Figure 2: Postulated anticancer mechanisms of action of artemisinins. (a) It has been postulated that bioactivation of artemisinin occurs in
the endosome after pH-induced release of iron from internalized transferrin. Iron activated-artemisinin generates carbon-centered radicals
which may mediate lysosomal disruption and generation of ROS resulting in mitochondrial damage, activation of caspases, and cell death.
(b) Alternatively, it has been suggested that only speciﬁc activation of artemisinin by heme or heme-bound protein generates cytotoxic-
carbon-centered radicals. In the mitochondrion, these adducts interfere with the electron transfer chain (ETC) by interacting with heme or
heme-bound proteins leading to generation of ROS and apoptosis. (c) ROS harboring may induce ER stress and (d) genotoxicity.
similar to that suggested in malaria parasites [31]. Thus,
activation of the mitochondrial intrinsic apoptotic pathway
isadownstreameventleadingtocelldeath[31](Figure 2).In
this model, artemisinins may be negatively controlling heme
synthesis and further increase cytotoxicity [31].
Despite the growing evidence of ROS-mediated damage
in many cell systems [31, 33, 35, 54], cell damage has been
also independently associated with oxidative stress [35]. Par-
ticularly, novel artemisinin dimers seem to exert antitumor
action with little or no ROS generation, however the un-
derlying mechanism of cytotoxicity is still under study [26].
It also remains unclear if artemisinins-induced necrosis may
be a ROS-independent mechanism of cell death [35].
The antineoplastic toxicity of artemisinins appears to be
also modulated by calcium metabolism [40, 55–57], endo-
plasmic reticulum (ER) stress [33, 40], and the expression of
the translationally controlled tumor protein, TCTP, a bind-
ing calciumprotein whichhasbeen alsopostulated asapara-
site target [5]. Although the expression of the TCTP gen,
tctp, was initially correlated with cancer cell response to
artemisinins, a functional role for TCTP in the artemisinin
action has yet to be found [58].
As for malaria parasites, the role of sarcoendoplasmic
Ca2+ ATPase (SERCA) as artemisinin target in cancer cells
has also been explored [40]. Previous evidence has revealed
that treatment with 10μM artemisinin increases calcium
concentrations as a result of SERCA inhibition [59]. How-
ever, studies on the mechanism of action of two artemisinin
dimers have shown that potent ROS-mediated induced ER-
stress after treatment was independent of SERCA inhibition
[40].Interestingly,thebehaviorofahighlyactiveartemisinin
dimer and thapsigargin, a well-known SERCA inhibitor,
seems to be similar but mediated by diﬀerent molecular
events [40]. In fact, thapsigargin lacks the endoperoxide
moiety and only generates discrete ROS levels. Nevertheless
the ER appears to be a relevant site for artemisinin action
as in HepG2 cells a ﬂuorescent derivative has been shown to
preferentially accumulate in this cell compartment [60].
Artemisinins have shown pleiotropic eﬀects through
diﬀerent experimental systems. It is also possible that the
underlying mechanisms mediating artemisinins cytotoxicity
may vary upon speciﬁc hallmarks or shifting characteristics
in cancer cell lines (Table 1). This will be only possible to
elucidateifthemoleculareventsinvolvedincounteringmali-
gnant cell proliferation are investigated in diﬀerent cell lines
under similar conditions.
4. ArtemisininsasAnticancer Drugs
4.1. Antitumor Eﬀects of Artemisinin and Its Derivatives.
Signiﬁcant antitumor activity of artemisinin and licensed
semisynthetic artemisinin derivatives has been documentedJournal of Biomedicine and Biotechnology 5
Table 1: Factors that may inﬂuence artemisinins response in cancer cells.
System Factor/characteristic
Cancer cell
Proliferating activity
Expression of transferrin receptors
Accumulation levels of iron
Levels of gene expression (i.e., proapoptotic and antiapoptotic genes)
Shifting hallmarks
Overexpression of potential molecular targets in some tumors
Cellular dependence on redox balance
Expression of antioxidant enzymes
Expression of estrogen receptors in breast cancer cells
Artemisinin
compound
Dose and time of exposure
Chemical structure: number of trioxane rings, for example, dimeric compounds can be up to >1000 fold-more
potent than monomeric artemisinins [61]
In dimeric endoperoxides: nature and stereochemistry of the linker
In novel compounds, electrophilic substitutions in the ring or those conferring lipophilicity. Boat/chair
conformation
in vitro and in animal models. Considerable research has
been focused on the most active compounds, namely, DHA
and artesunate. One study that tested 55 cell lines from
the Developmental Therapeutics Program of the National
Cancer Institute (NCI) showed that artesunate displays inhi-
bitory activity against leukemia, colon, melanoma, breast,
ovarian, prostate, central nervous system (CNS), and renal
cancer cells [5]. Dihydroartemisinin has also remarkable
antineoplasticactivityagainstpancreatic,leukemic,osteosar-
coma, and lung cancer cells [62]. Moreover, artemisone has
shown better activity than artemisinin and considerable syn-
ergistic interactions with other anticancer agents [63].
Artemisinin has been found to act either directly by in-
ducing DNA damage (genotoxicity) or indirectly by interfer-
ing with a range of signaling pathways involved in several
hallmarks of malignancy. However, direct DNA damage is
only described in speciﬁc systems, while indirect eﬀects are
more commonly refereed in the literature. In pancreatic cells
(Panc-1), artesunate caused DNA fragmentation and mem-
brane damage. Interestingly, low doses of artesunate were as-
sociated with oncosis-like cell death, whereas higher concen-
trations induce apoptosis [51]. Extend and type of damage
seem to depend on the phenotype and the origin of cell
line, and it may also vary in a time- and dose-dependent
manner (Table 1). Notably, higher sensitivity to artesunate
was observed in rapidly growing cell lines when compared
with slow growing cancer cells [5].
Alternatively, DHA, artesunate, and artemether are likely
to modulate genes and proteins coordinating growth signals,
apoptosis, proliferation capacity, angiogenesis and tissue
invasion, and metastasis. A complex network of interactions
throughdiﬀerentpathwaysmayenhancetheanticancereﬀect
of these endoperoxide drugs leading to cancer control and
cell death (Table 2).
4.1.1. Artemisinins Counter Cancer Proliferative Capacity. In
normal cells, cyclin-dependent kinases (CDK) are the pro-
teins translating signals in order to push cell through the cell
cycle. Normal growth relies on the ability to translate signals
i no r d e rt or e p l i c a t ea n dd i v i d ei na ne ﬀective manner [64].
Uncontrolled proliferation in cancer cells is the result of
mutations inducing ampliﬁcation of growth signals, dereg-
ulation of checkpoints, and loss of sensitivity to growth inhi-
bitors [65]. Abnormal cell growth is also triggered by dereg-
ulation of programmed cell death or apoptosis [65]. Arte-
misinin and its semisynthetic derivatives are able to eﬀec-
tively induce cell growth arrest in cancer lines either by
disrupting the cell cycle kinetics or by interfering with
proliferation-interacting pathways. Dihydroartemisinin and
artesunate are very potent growth inhibitors with multiple
studies pointing to DHA as the most potent anticancer
artemisinin-like compound (DHA > artesunate > arteeter >
artemether) [5, 66]. Recently, artemisone has shown impres-
sive antitumor eﬃcacy in 7 cells lines including melanoma
and breast cancer cells [63]. Artemisinin compounds have
been shown to exert cytostatic and cytotoxic action on can-
cer cells [63, 67]. Artemisinin-induced growth arrest has
beenreportedatallcellcyclephases;however,arrestatG0/G1
to S transition seems to be more commonly aﬀected [5]
(Table 2). Arrest at all cell cycle phases at the same time
has been interpreted as a cytostatic eﬀect [63]. Disruption
of the cell cycle at G2/M was observed after DHA treatment
in osteosacorma, pancreas, leukemia [68] and ovarian cancer
cells [69]( Table 2). Similarly, artesunate interferes with G2
in osteosarcoma, ovarian, and other diﬀerent cancer lines
(Table 2). The underlying mechanisms of artemisinins-in-
duced growth arrest include alterations in the expression and
activity of regulatory enzymes of the cell cycle, such as
CDK2-4 and -6 and D type cyclins (G1-to-S-phase transi-
tion) or CDK1, and A-type cyclin (G2/M) [70–72]. The anti-
proliferativeactionofartemisinininducesdownregulationof
CDK transcription, inhibition of CDK promoters or increase
of p21, p27, and CDK inhibitor [72]( Table 2). Inhibition
of proliferation may be also attributed to downregulation of
interacting proteins targeting multiple pathways [72]. It has6 Journal of Biomedicine and Biotechnology
Table 2: Antitumor eﬀects of artemisinins.
Cmpd Cancer/cell line Eﬀect Event/mechanism Refs
DHA/ART Osteosarcoma Growth arrest G2/M, decreased survivin [73]
4 cell lines with diﬀerent p53
status Apoptosis Increased Bax, activation of caspase 3,8,9
Decreased Bc12, Cdc25B, cyclin B1, NF-κB [44]
DHA Hepatoma (diﬀerent cell lines) Growth arrest G1, decreased cyclin D, E, CDK2-4, E2F1
Increased Cip 1/p21, Kip 1/p27 [67]
Apoptosis
Increased Bax/Bcl2 ratio, activation of caspase 3
Increased poly ADP-ribose polymerase
Decreased MDM2
DHA/ART Neuroblastoma Growth arrest G1 [52]
Apoptosis Activation of caspase 3
DHA Pancreas (BxPC3 RFP)
Growth arrest G1, decreased cyclin D1, increased p21 [74]
Apoptosis Increased Bax, decreased Bcl2 [74, 75]
Angiogenesis
Decreased VEGF [75, 76]
Decreased NF-κB DNA binding [74, 76]
IL-8, COX2, MMP9 [76]
DHA
Human promyelocytic Growth arrest G1 [33, 34]
Leukemia (HL-60) Apoptosis ER stress, degradation of c-MYC [33]
Colorectal cancer (HT116) Increased GRP78 [34]
DNA damage [33]
DHA
Lung cancer (SPCA1)
Apoptosis
Decreased survivin [56]
(PC-14) Increased calcium levels, increased p38 MAPK [57]
(ASTC-a-l) Increased oxidation, activation caspase 3,9,8
Bax translocation [54]
DHA/ARS Human ovarian cancer (cell
panel, A2780, OVCAR-3)
Growth arrest G2 [69]
Apoptosis Increased Bax-Bad, decreased Bclx-Bcl2 [69, 77]
Activation caspase 3/9 pathway [69, 77]
DHA Lymphatic endothelial cells Apoptosis Increased Bax, decreased Bcl2
Decreased VEGFR-3/FL-4 [78]
DHA Melanoma (A375, G361, LOX) Apoptosis Increased oxidative stress, increased NOXA
Activation caspase 3 [79]
DHA Jurkat T Lymphoma Apoptosis
DNA damage
Increased oxidation, increased NOXA
Increased Bak, activation of caspase 9
[80]
DHA Fibrosarcoma (HT 1080) Migration/invasion
Decreased NF-κB, AP-1
Decreased activation of MMP2, MMP9
Decreased PKC α/Raf/ERK and JNK
[81]
DHA Glioma cells (C6) Apoptosis Decreased HIF 1α,V E G F [ 41]
DHA Chronic myeloid leukemia
(K562 cells) Growth arrest G2, decreased PCNA, cyclin B1, D1, E1 [82]
CDK2-4, E2F1, DNA-PK, DNA-topo1, JNK VEGF [68]
ART Angiogenesis Decreased VECF [82]
DHA Lewis lung carcinoma
Angiogenesis Decreased VEGF-C, IL-1 β-induced p38 [83]
MAPK activation
Decreased VEGF receptor KDR/ﬂk-1 [84]
DHA/ART
Cervix carcinoma (HeLa)
Human papillomavirus
immortalized/transformed
cells
Apoptosis Activation of caspase 9 [85]
ART
Leukemia, melanoma,
non-small cell lung cancer,
colon, renal, ovarian, prostate,
CNS; prostate, breast cancer
(NIC cell panel)
Growth arrest G0/G1, decreased CDK2, CDC25A
G2/M, decreased cyclin B1 [5]Journal of Biomedicine and Biotechnology 7
Table 2: Continued.
Cmpd Cancer/cell line Eﬀect Event/mechanism Refs
ART Endometrial carcinoma
(HEC-1B)
Growth arrest G0/G1
[86] Apoptosis Activation of caspase 3, decreased COX-2
Angiogenesis Increased E-cadherin
ART Pancreatic cancer (BxPC3,
MiaPaCa-2) Apoptosis Activation of caspases 3, 7
Inhibition of topoisomerase II a [87]
ART Non-small cell lung cancer
(SPC-A1) Metastasis
Decreased MMP2, transactivation of AP-1 [56, 88]
NF-κB
uPA promoter [88]
MMP7 [56]
ART Colorectal (CLY, HT29, Lovo) Metastasis Increased E cadherin
Decreased Wnt-signalling pathway [89]
ART Mouse myeloma cell line
SP2/0
Growth arrest G0/G1 [90]
Apoptosis Decreased NF-κB p65, increased IκBα
ARS
Hepatocellular cancer cells
(HepG2, SMMC-7721)
Metastasis Increased TIMP2, Cdc42, E cadherin [91]
Decreased MMP2
Nasopharyngeal cancer lines
(CNE-1 and CNE-2) Growth arrest G1 [92]
Melanoma (A375P, A375M) Growth arrest — [93]
Migration Decreased MMP2, αvβ3 integrin
ATM
Colorectal (HCT116, SW480) Growth arrest G1,S ,G 2, decreased CDK1
[63] All phases
Breast (MCF-7) G1, decreased CDK4, cyclin D1
Abbreviations: Cmpd: compound; DHA: Dihydroartemisinin; ART: artesunate, ARS: artemisinin, ATM: artemisone.
been shown that DHA treatment in pancreatic cells (BxPC3,
AsPC-1)inhibitsviabilitybydecreasinglevelsofproliferating
cell nuclear antigen (PCNA) and cyclin D with parallel
increaseinp21[74].Anotherstudyinthesamesystemshows
that DHA counters NF-κB factor activation leading to inhi-
bition of its targets in the proliferation (c-myc, cyclin D)
and apoptotic pathways (Bcl2, Bcl-xl) [94]. Downregulation
of survivin, a protein modulating apoptosis and G2/M cell
cycle progression [95], was observed after treatment with
DHA in lung cancer cells (SPC-A1) [94]. A similar eﬀect was
described by Qiang et al. in artesunate- treated osteosarcoma
cells [44]. In prostate cancer, DHA induces cell cycle arrest
by disrupting the interaction of Sp1 (speciﬁcity protein 1)
and the CDK4 promoter [96]. Dissociation of the Sp1-CDK4
complex promotes caspase activation and cell death. In addi-
tiononeworkhasidentiﬁedartesunateasatopoisomeraseII,
an inhibitor which inhibits growth by interaction with mul-
tiple pathways [87]. Overall, artemisinins seem to be inter-
fering with several pathways that are common to diﬀerent
cancer entities.
4.1.2. Proapoptotic Eﬀect of Artemisinins. Apoptosis is a
widely studied mechanism in antitumor therapy as its ma-
nipulation is aneﬀectivestrategyforcancercontrol.This cel-
lularprocessismediatedbyabalancebetweentheBcl2family
genes, the proapoptotic Bax, and the antiapoptotic Bcl2
and their eﬀects on the mitochondria [97, 98]. An increase
in the Bax/Bcl2 ratio induces the release of cytochrome c fol-
lowed by sequential activation of caspases and culminating
with cell death [98].
Apoptosis is a common and rapid artemisinin-induced
eﬀect observed in many cancer and cell lines. Treatment with
200μM DHA in leukemia cells induced apoptosis after 1
hour of exposure [32]. Artemisinin sensitivity has been cor-
related to the level of expression of antiapoptotic (Bcl2) and
proapoptotic genes (Bax) in a cancer cell line [61, 97, 99]
(Table 1).Ingeneral,theapoptoticeﬀectsofartemisininhave
been attributed to activation of the intrinsic pathway. Hence,
mitochondrial membrane damage is thought to have a piv-
otalroleinthecascadeofcelldeathevents.Manystudieshave
revealed that artemisinin-like compounds induce apoptosis
by modulating the Bax/Bcl2 ratio [33, 44, 54, 63, 75, 77, 78,
86, 99]. Consistent with these observations, DHA and arte-
sunate, in a panel of osteosarcoma cells, caused cytochrome
c release, Bax overexpression, increase in Bax/Bcl2 ratio [44,
73], and activation of caspases 3 and 9. DHA also activates
caspase 8 and decreases the levels of CDC25B, cyclin B1, and
NF-κB[73].Inthesamesystem,artesunateexposuredepletes
survivin which has also been involved in the apoptotic DHA
response in lung cancer cells [56]. Similar events have been
described in hepatoma cancer lines treated with DHA, parti-
cularly in this system DHA and the prototype drug arte-
misinin seem to have similar potency [67]. A microarray
analysis has correlated the expression levels of c-MYC with
enhanced DHA-induced apoptosis. Leukemia (HL-60) and
coloncancercells(HCT116) expressing high levelsof c-MYC
are signiﬁcantly more sensitive to the DHA proapoptotic
action. Moreover, knockdown of c-myc in HCT116 depleted
DHA-associated cell death [33]. Downregulation of c-myc8 Journal of Biomedicine and Biotechnology
mayalsocorrelatewithinducedG1 arrestinthiscellline[33].
Studies in metastatic melanoma (A375, G361 cell line) and
Jurkat T lymphoma cells have associated the elevated apop-
toticactionofDHAwithupregulationofNOXA(aproapop-
totic protein), caspase 3 activation, and oxidative stress [79,
80]. In lung cells, the apoptotic eﬀect of DHA occurs with
increasing calcium concentration and activation of p38 [56,
57].
In some studies alterations on molecules acting on the
extrinsic apoptotic pathway have also been described [54].
DHA seems to increase the transcription of the cell death
receptor 5 (DR5) promoter and induces DR5 in diﬀerent
prostate cancer lines. In fact, a combination treatment with
TRAIL, a DR5 ligand, strongly enhances DHA proapoptotic
action by up to 35% on this system [100].
Artemisinins usually promote apoptosis rather than nec-
rosisinmostofthesystems,howeverinsomecasesbothapo-
ptosis and necrosis have been reported. Induction of apopto-
sis is a major beneﬁt of artemisinins’ antitumor action as it
prevents the collateral eﬀects of inﬂammation and cell dam-
age caused by necrosis. Artemisinin-induced necrosis has
been associated with low levels of ATP and defective apop-
totic mechanisms in some cell lines [35].
4.1.3. Artemisinins and Metastasis/Invasion Inhibition. The
ability of malignant cells to invade has been associated with
high mortality and morbidity in cancer patients. The spread
of cancer cells to other organs is a process in which malig-
nant cells readily invade through the extracellular matrix,
reach and survive in the bloodstream, and ﬁnally seed at
distant organs [101]. To achieve invasion, the cancer cell
requires the loss of expression or function of E-cadherin, a
calcium-binding transmembrane molecule involved in cell-
cell adhesion. A range of genes encoding extracellular matrix
processing proteases, motility factors, and adhesion proteins
are also acting at diﬀerent steps in the metastatic process
[101]. Recently, PAI-1 and TIMP-1 known as endogenous
protease inhibitors have also been shown to be involved in
cancer metastasis [102]. An invaluable beneﬁt of artemisinin
is its relevant antimigratory activity in highly aggressive and
invasive cancer entities [56, 59, 88, 91]. Antimetastatic activ-
ity of artemisinins has been correlated with modiﬁed expres-
sion of the matrix metalloproteinases (MMP) gene family
and their eﬀects on αvβ3 integrins [93]. In hepatoma cells
(HepG2 and SMMC 7721), treatment with 12.5μMa r t e -
misinin depleted migration linked to a decrease in MMP2
with concomitant increase in TIMP-2. Inhibition of metas-
tasis is achieved as artemisinin increases cell-cell adhesion
by enhancing E-cadherin activity and Cdc42 activation [91].
In addition, it has been found that some cancer cells may
havespeciﬁcproteinscointeractingatdiﬀerentpathways.For
example, in non-small cell lung cancer [56]a n dﬁ b r o s a r -
coma, DHA treatment induced low levels of MMP2, MMP7,
or MMP9 driven by AP-1 and NF-κB transactivation or inac-
tivation[81].PreviousstudieshaveshownthatMMP2isreg-
ulated by Sp-1 transcription factor activity [103], moreover
DHA-induced disruption of Sp-1 molecular interactions has
been postulated as a crucial event for DHA regulation eﬀects
on diﬀerent pathways [72]. Other investigations have found
that in mouse lung Lewis cancer, lymphoid node metas-
tasis and lymphangiogenesis were retarded by artemisinin-
mediated inhibition of vascular endothelial growth factor C
(VGF-C) [83].
4.1.4.ArtemisininsandAngiogenesisInhibition. Asmalignant
tissuesgrow,metastasesandsolidtumorsrequireextrablood
supply for thriving and survival. Thus, cancer cells induce
neovascularisation by regulating proteins and pathways in-
volved in the generation and restructure of new vasculature
[101]. Angiogenesis process leads to enhanced proliferation
of endothelial cellsthrough induction of vascularendothelial
growth factor (VEGF), ﬁbroblast growth factor (FGF), its
receptors,andcytokines[101].Thiseventoccursviamultiple
mechanisms including hypoxia-driven activation of expres-
sion of HIF-1α and the aryl hydrocarbon receptor nuclear
translocator (ARNT) [104]. Angiogenesis control is medi-
ated by angiostatin, endostatin, thrombospondin, TIMPs,
PAI-1, and others [101]. Due to their role in tumor survival,
the proangiogenic factors and the molecules involved in
their regulatory networks are relevant drug targets. A micro-
array-based study revealed that artemisinins, artesunate and
other derivatives inhibit neovascularisation by modulating
gene expression of angiogenic factors [105]. Artemisinins
responses seem to be mediated by downregulation of growth
factors (VEGF, FGF) [82, 106], HIF-1α [107], new vessel
mediator angiogenin (ANG), the cysteine-rich angio-
genic inducer (CYR61), some metalloproteinases (MMP9,
MMP11, and BMP1), and collagens [105]. In parallel, arte-
misinins- induced upregulation of angiogenesis inhibi-
tors was observed [105]. These ﬁndings have been supported
by experimental investigation in diﬀerent systems, unveiling
other molecular interactions. Exposure of human umbilical
vein endothelial cells to 50μM DHA prevents angiogenesis
by depleting the levels of the VEGF ﬂt-1 and KDR/ﬂk-
1-receptors. Similar eﬀects were reproduced in lymphatic
endothelial cells and Lewis lung carcinoma [78, 84]. In pan-
creatic cells (BxPc-3) and BalB/c nude mice, DHA induced
inhibition of NF-κB DNA binding and downregulation of its
angiogenic-related targets such as VEGF, IL-8, COX2, and
MMP9 [76]. Reduced levels of NF-κB have been previously
associated with proliferation and metastasis inhibition [33,
81, 90, 94] suggesting that NF-κBr e g u l a t i o nm a yb eak e y
role in the multimodal action of DHA in this system. NF-κB
is a crucial factor regulating multiple processes and it has a
key role in the anticancer drug response. It is activated by
DNA damage and it is a mediator of apoptosis resistance in
response to drug pressure.
Other anticancer properties have also been attributed to
artemisinins. Artesunate has shown its ability to revert cel-
lular transitions allowing re-diﬀerentiation of tissues by neg-
ative control of Wnt-signaling pathway [89]. Notably, arte-
sunate has been found to be more eﬀective in less diﬀerenti-
ated cell lines [89].
4.2. Antitumor Action of Artemisinins in Resistant Cancer
Cells. One major obstacle for a successful anticancer therapy
is the development of resistance over time. Many aggressive
tumors become refractory to anticancer therapy with hardlyJournal of Biomedicine and Biotechnology 9
any chemotherapeutic alternatives. A leading cause of drug
resistance is the drug eﬄux generated by overexpression
of membrane protein pumps, which results in ineﬀective
lowdrugconcentrations[108].Anticanceractivityofartemi-
sinins has shown to be unaﬀected in otherwise resistant and
multiresistant cancer cells. One study using the 55 NCI cell
lines and microarray analysis revealed that genes related with
resistance to the established anticancer drugs such as MDR1
(Pgp), MRP1, and BCRP showed no impact on the activity
of artemisinins [5]. This was substantiated when no eﬀects
on the artesunate growth inhibition proﬁle were observed in
multidrug resistance HL-60 cell lines overexpressing MRP-
1 and BCRP-overexpressing cells, suggesting that antitumor
activity of artemisinin is preserved when resistance to
other agents is present [5]. Artemisinins are eﬀective in a
broad range of resistant cancer lines including doxorubicin,
metrotexate, and hydroxyurea-resistant lines with no cross-
resistance [5]. Further investigation has shown that arte-
sunate proapoptotic eﬀect is not aﬀected in a doxorubicin-
resistant leukemia cell line; instead artesunate potentiates
doxorubicin apoptotic eﬀects [4]. In another study, anti-
cancer potency of artesunate is preserved in chemoresistant
and chemosensitive neuroblastoma cell lines and primary
neuroblastoma cultures [52]. In this system, sensitivity to
artesunate was not aﬀected in vincristin, doxorubicin, cis-
plastin, topotecan, mephalan, and ectoposide-adapted cells
with IC50s ranging from 1.4–2.7μM similar to that of the
parent sensitive cell line [52]. Only one cell line showed
low sensitivity to artesunate which was related to low ROS
formation and increased expression of gluthatione cysteine
ligase (GCL) [52]. Depletion of glutathione mediated by a
GCL inhibitor improved artesunate sensitivity in this cell
line [52]. P-glycoprotein (Pgp) or p53 attenuation did not
aﬀect sensitivity to artesunate [52]. DHA has shown the
lowest IC50 in some cell lines such as cholangiocarcinoma
(CL-6) and hepatocarcinoma (Hep G2) compared to other
anticancer agents; moreover, upregulation of MDR1, MRP1-
2,o rMRP3 shows no eﬀect on potency [109]. Lack of cross
resistance between anticancer agents and artemisinins might
be based on diﬀerent mechanisms of drug action and/or
resistance. Most of the conventional anticancer agents are
nucleosideanalogs,whereasartemisininsactionisthoughtto
be mediated by a ROS-dependent mechanism. Furthermore,
in erythromyelogenous leukemia and human small cell lung
cancer, artemisinins show no signiﬁcant inhibition towards
Pgp or MRP1 [4], thus in principle overexpression of protein
pump may not aﬀect artemisinin’s potency. In another sys-
tem however, artemisinin (the prototype drug) increases do-
xorubicin resistance by upregulating mdrp through a mecha-
nism that will be discussed later.
4.3. Interactions of Artemisinins and Standard Anticancer
Chemotherapy: Artemisinin Combination Therapy (ACT) for
Cancer? Existing anticancer therapies predominantly target
cancer proliferation either with chemotherapeutic agents,
ionizing radiation or direct toxicity on growth factor signal-
ing pathways. In a combination therapy for cancer, the anti-
neoplastic action of artemisinin may contribute to an inde-
pendent antitumor activity with no additional side eﬀects.
Thebeneﬁtsofcombiningartemisininswithotheranticancer
agents have been investigated showing that multifactorial
action of artemisinin in diﬀerent pathways may improve
overall activity (synergism).
It has been reported that resistant cancer cell lines be-
come sensitive by adding artemisinin to the conventional
treatment (chemosensitization). Interestingly, DHA and
artesunate have exhibited the strongest chemosensitizing/
synergistic eﬀects [4, 110], whereas the prototype drug arte-
misinin shows only additive and antagonistic interactions
(Table 3). DHA signiﬁcantly improves the anticancer eﬀect
of gemcitabine, an anticancer drug used in pancreatic cancer
which develops resistance over time. In vitro and in vivo ana-
lysis in pancreatic cells demonstrated a DHA-induced in-
crease in growth inhibition and apoptosis by 4- and 2-fold,
respectively,comparedwiththoseobtainedwithgemcitabine
alone [94]. A dual action of DHA in potentiating gemcita-
bine activity and possibly counteracting resistance has been
attributed to DHA inhibition of gemcitabine- induced NF-
κB activation and subsequent action on its targets [94]. A
similar eﬀect has been shown in hepatoma cancer cell lines
irrespective of their p53 status [67]. DHA synergistically en-
hances tumor growth inhibition by 45% when in combina-
tion with gemcitabine, whereas artemisinin, the prototype,
only induces additive eﬀects [94].
Consistent with this observation, a greater antitumor ac-
tivity was observed when DHA was used in a combination
with cyclosphosphamide in murine Lewis lung carcinoma
cell line or in combination with cisplatin in non-small cell
lung cancer A549 in mice [84]. In rat C6 glioma cells, ad-
ditionof1μMDHAincreasedby177%thecytotoxiceﬀectof
temozolomide,aDNA-alkylatingagentusedinthetreatment
of brain cancer. Further investigation found that DHA
promotes apoptotic and necrotic activity of temozolomide
through ROS generation [107]. Recently, an enhancement of
artesunate anticancer activity has been observed in diﬀerent
combination regimens. A striking synergy was achieved in
combinations of artesunate and the immunomodulator
drug, lenalidomide [111].
However, the beneﬁts of an artemisinin combination
therapyneedtobecarefullydissected.Therapeuticeﬀectsare
inﬂuenced by the mode of action of the drugs and multiple
interactions in particular systems and schedules. Recently,
Gravetth et al. showed that gemcitabine has only additive ef-
fects when combining gemcitabine and artemisone in colon
and breast cancer cells [63]. In cancer colon cells (HT-29),
it has been suggested that artemisinin may impair doxoru-
bicin activity possibly by countering the doxorubicin eﬀect
on NF-κB inhibition [59]. The same authors have reported
artemisinin-induced resistance in the same system through a
diﬀerent mechanism. Thus, it has been postulated that arte-
misinin exposure inhibits SERCA with subsequent accumu-
lation of calcium. As a result, Pgp is upregulated and leads to
generation of doxorubicin resistance cells [59]. By contrast,
pretreatment with a calcium chelator reverted the cells to a
sensitive phenotype [59]. Notably, DHA and artesunate have
not been evaluated in this system; it remains to be elu-
cidated whether the most potent chemosensitizers have
similar eﬀects on this cell line. So far, artesunate or DHA10 Journal of Biomedicine and Biotechnology
Table 3: Drug interactions of artemisinins.
Drug combination Cancer/cell line Eﬀect Refs
DHA + Temozolomide Rat C6 glioma cells Increased apoptosis, ROS
Induced necrosis [107]
DHA + Cyclophosphamide Lewis lung carcinoma
Increased apoptosis, decreased VEGF receptor
KDR/ﬂk-1
Apoptosis
[84]
DHA + Cisplatin Human non-small cell lung
cancer (A549) Decreased metastasis [84]
DHA + Gemcitabine
Pancreas (Panc-1) Inhibition of proliferation, decreased cyclin D1
Increased apoptosis, increased Bax/Bcl2 ratio,
activation of caspase 3
[94]
Hepatoma (cell panel) Increased growth inhibition by 45% [67]
DHA + Butyric acid Human lymphoblastoid
leukemia (Molt-4) Synergistic. Depletion of cancer cells [110]
DHA + Radiation Glioma cells
U373MG
Increased cytotoxicity
Inhibition of radiation-induced GST [53]
DHA + Carboplatin Ovarian cancer cells
(A2780, OVCAR-3)
Increased growth inhibition through death receptor
and mitochondrial mediated pathways [77]
DHA + TRAIL Prostate cancer (DU145,
PC-3, LNCaP) Increased apoptosis extrinsic and intrinsic pathways [100]
ART/DHA + Doxorubicin
+ Pirarubicin
Leukemia (K562/adr)
Small cell lung cancer
(GLC4/adr)
Synergistic [4]
ART + Lenalidomide Lung (A549) and breast
(MCF-7) Decreased IC50 by 48% [111]
ART + Oxiplatin Colon (HT 1116) Additive. Sensitising eﬀect
[111] ART + Gemcitabine Breast (MCF-7) Additive
Lung (A549) Additive
ATM + Oxiplatin
ATM + Thalidomide
ATM + Gemcitabine
Colon (HCTl16, SW480)
Breast (MCF-7) All additive [63]
ARS + Hyperbaric oxygen
(HBO2) Molt-4 human leukemia 22% decrease in growth [112]
ARS + Doxorubicin Colon cancer(HT29) Predicted as antagonic, mediated by activation of
NF-κB/overexpression of Pgp [59]
ARS + Oxiplatin Colon (HCTl16, SW480) Antagonism
[63] ARS + Thalidomide Additive
ARS + Gemcitabine Breast (MCF-7) Antagonism
Abbreviations: HBO2: hyperbaric oxygen.
in combination with doxorubicin and pirarubicin showed
chemosensitizing eﬀect in leukemia and human-small-cell
cancer-resistant cell lines, but no further increase of sensi-
tivity was observed in the sensitive parent cell lines [4]. The
chemosensitising eﬀect was independent of Pgp inhibition
[4]. Overall, this evidence suggests that DHA and artesunate
have remarkable ability to potentiate antitumor agents and
to counter tumor resistance.
Artemisinins also improve ionizing-based therapies. In
glioma cells U373MG, DHA treatment inhibits the radia-
tion-induced expression of GST with concomitant ROS gen-
eration.AcombinationtreatmentwithDHAhasbeenshown
to be more eﬀective than radiation or DHA alone [53]. The
adjuvant eﬀect of artemisinin in other cancer treatments in-
cluding hyperbaric oxygen has also been reported [112].
4.4.ArtemisininResistance. Asalientfeatureofartemisininis
that artemisinin resistance in vitro or in the ﬁeld has yet to be
conﬁrmed after 30 years of use as an antimalarial. Clinically,
tolerance has been reported in patients with therapeutic
failure. However, in vitro tolerant strains are usually unstable
and only develop after several years of continuous drug
exposure [113]. The multimodal action of artemisinins at
diﬀerent cancer pathways might also predict a delay of in-
duced resistance in malignant cells. Indeed, only few cell
lines have shown intrinsic low sensitivity or no response to
artemisinin or its derivatives. For example, artemisinin (the
prototype drug) seems to be less active in breast cancer cells
(MCF-7) and gastric cancer (MKN) [93]. Some studies in
breast cancer cells have suggested that artemisinin response
ma ybemediatedbyestrogenreceptors(ERαandERβ)whichJournal of Biomedicine and Biotechnology 11
a r ei n v o l v e di nc e l lp r o l i f e r a t i o n( r e v i e w e di n[ 72]). Inter-
estingly, it has been documented that in breast cancer cells,
disruption of iron metabolism may enhance potency of
doxorubicin and cisplatin [114]. The low response to arte-
misinin has been also associated with overexpression of
BMI-1 in highly metastatic nasopharyngeal cancer cell lines
(CNE-1, CNE-2) [92]. A recent study found some levels of
cross resistance to artesunate and DHA in a unique cisplatin
chemo-resistant cell line. This eﬀect was partially reverted by
L-buthionine-S,R-sulfoximine, an inhibitor of the antioxi-
dant GLC [52].
However, in vitro resistance has already been developed
under experimental conditions. Microarray and experimen-
tal studies using knockouts and transfected cells indicate
that upregulation of the tumor suppressor p16INK4A and the
antioxidant protein, catalase, may confer resistance to arte-
sunate independent of the p53 status [115]. Recently, con-
cerns have arisen after Baechmeier et al. showed that a 24h
preincubation with 20μM artesunate induces resistance in
highly metastatic breast cancer cells. Pretreated MDA-MB-
231 metastatic cells were completely refractory to further
artesunate treatment, whereas a similar treatment in MDA-
MB-468, a non-metastatic cell line, renders less sensitive
cells. Further investigation on the mechanism of artesunate-
acquired resistance indicates that upregulated transcription
of NF-κB, AP-1, and NMP-1 overcome artesunate apoptotic
and antimetastatic action and allows tumor progression
[116]. It is not clear, however, whether artesunate-induced
resistance and loss of sensitivity are preserved after long-
term cell subculturing. It also remains to elucidate if other
semisynthetic endoperoxides may induce a similar eﬀect or
whether a combinational therapy may delay or revert the
eﬀect on cell lines bearing this phenotype.
4.5. Artemisinins Toxicity. Dose-dependent toxicity is a
majordrawbackthathampersanticancertherapy. Thisprob-
lem may be overcome by enhancing anticancer activity and
thus reducing toxic drug concentrations. DHA is the most
active and neurotoxic artemisinin derivative [117]. Neuro-
toxicity has been reported in animal studies in a dose- and
time-dependent manner (≥7 days) [118–120]. The toxicity
of artemisinin-like compounds has been associated with
long-term availability, whereas short-term peak concentra-
tions are not toxic [121]. Thus, rapid elimination of artemi-
sinin in oral formulations is safer than slow-release or
oil-based intramuscular formulations [6, 121]. Remarkably,
although artemisinins derivatives have been widely used as
antimalarials,theirtoxicityinhumanshavebeenshowntobe
negligible. In cancer therapy, artemisinin may have multiple
beneﬁts as it can be used in combination with no additional
side eﬀects, but also it enhances potency and reduces doses
of more toxic anticancer partners. Clinical doses used in
malariatreatmentafteradministrationof2mg/kginpatients
rise plasma concentrations of 2640 + 1800 μg/mL (approxi-
mately 6.9±4.7mM) which can be considered up to 3 orders
of magnitude higher than those artemisinin concentrations
with antitumor activity [5]. It becomes relevant to closely
monitor the safety of long-term artemisinin-based therapies
as severe side eﬀects may be highly unusual but signiﬁcant.
So far, artemisinin treatments for as long as 12 months have
been reported with no relevant side eﬀects [30, 122, 123].
However, an extremely rare case of toxic brainstem ence-
phalopathy was described in a patient after a 2-week herbal/
artemisinin combination (400mg) regimen for breast cancer
[124]. Brainstem neurotoxicity has been reported in animal
studies and associated with long-term (>28 days) and high-
dose treatments [118]. Recently, a fatal case of overdosing in
a child who was taking antimalarial treatment was reported
[125].
4.6. Artemisinins in Clinical Trials. Antitumor activity of ar-
temisinin has also been documented in human trials [126]
and individual clinical cases [30, 122]. Artemether and arte-
sunate have been used in cancer therapy with good tolerabil-
ity and lack of signiﬁcant side eﬀects.
Artesunate was successfully used in the treatment of lary-
ngealsquamouscellcarcinomaandsubstantiallyreducedthe
size of the tumor (by 70%) after two months of treatment
[122]. Furthermore, artesunate increased survival and sub-
stantial metastasis reduction when used in combination with
standard chemotherapy in patients with malignant skin can-
cer [30]. Another report describes a beneﬁcial improvement
in a patient with pituitary macroadenoma who was treated
with artemether for 12 months [123]. Artemether has longer
half-life and easily crosses the blood-brain barrier which is
crucial for brain tumor treatment.
Similarly, a clinical trial in 120 patients with advanced
non-smallcelllungcancerhasshownthatartesunateincom-
bination with a chemotherapy regimen of vinorelbine and
cisplatin elevated 1-year survival rate by 13% with a signiﬁ-
cant improvement in disease control and time to progression
[126]. No additional artesunate-related side eﬀects were re-
ported [126]. In Germany, a trial in patients with advanced
breast cancer is currently ongoing. Tolerability to a combi-
nation therapy of 4-week artesunate will be assessed in this
trial. Another trial in UK in colorectal adenocarcinoma to
evaluate anticancer action and tolerability of artesunate was
completed last year, but the results have not been published.
5. Anticancer Action of Novel
ArtemisininsDerivatives
5.1. Novel Semisynthetic Derivatives with Antitumor Action.
Imperative need of highly eﬀective compounds with enhan-
ced pharmacological properties has led to the design of novel
endoperoxide compounds with selective toxicity toward can-
cer cells. Considerable progress has been made in the design
of novel compounds with enhanced potency at the nanomo-
larrange,increasedselectivity,andlowtoxicityinvitro.I thas
beenreportedthattriazolylsubstitutedartemisinins-induced
signiﬁcant growth inhibitory eﬀect [127]. Independent of
stereo-orregion-chemistry,stronginhibitionwasinﬂuenced
by the functional group attached to the triazole ring. Sub-
stituted compounds with a penthyl benzene group showed
the highest antiproliferative activity ranging from 0.07 to
0.39μM72hIC 50 in 6cancerlines[127].Recently,Fenget al.
synthesized a series of dihydroartemisinin derivatives via an
aza-Michaeladditionreactionwithhighselectivityindexand12 Journal of Biomedicine and Biotechnology
IC50 in the nanomolar range against HeLa cells (0.37μM)
[128]. In a series of deoxoartemisinins and carboxypropy-
ldeoxoartemisinins, antitumor eﬀect was associated with
boat/chair conformations and drug-receptor interactions
[129].
Diﬀerent from their antiparasitic activity, it has been
found that dimeric and trimeric artemisinin derivatives dis-
play much higher antitumor activity than their monomeric
counterparts. Inthe lastdecade, anincrease in the number of
outputs in artemisinin dimeric compounds with anticancer
activity has been observed. These compounds have shown
IC50 ranging from 0.014 to 6μM[ 130, 131]. Potent antican-
cer toxicity has been correlated with the nature of the linker
[132] and with lipophilicity or electrophilic substitutions
[66]. Posner et al. developed a series of artemisinin-trioxane
derivate dimers from which two phosphate esters displayed
nanomolar growth inhibitory values in the NCI 60 human
cell line screen. Further investigation in vitro showed that in
HL-60 cells, these compounds are more potent than dox-
orubicin, whereas their strongly anti-parasitic monomeric
counterparts showed no anticancer activity. As suggested by
the authors, two trioxane units in addition to the nature of
the linker may be relevant in conferring potent anticancer
activity [132]. Homodimers of artesunic acid have also
nanomolar inhibitory values when tested in chemo-resistant
and sensitive leukemia cells. Notably, the artesunic dimer
seems to be 6-fold more potent in the multiresistant Pgp
overexpressing cells (CEM/ADR500) than in its sensitive
counterparts. Anticancer activity was attributed to apoptosis
induction, arrest of cell cycle at G0/G1, and ROS generation
[131]. In prostate cancer cells (LNCaP, TRAMP CIA, and
C2H),twoC10non-acetaltrioxanedimersdisplayeda3-fold
increaseinpotencycomparedtodoxorubicin(17-18nMver-
sus 45.3nM resp.). The dimers induced arrest at G0/G1 me-
diated by decreasing cyclin D1, cyclin E, CDK2, and an in-
crease in p21 and p27. They also show proapoptotic action
through upregulation in Bax expression [130].
In many studies, there has been an emphasis on the
nature and stereochemistry of the dimer linker which may
inﬂuenceanticanceractivity.However,ithasalsobeenshown
that the linker by its own is inactive. Morrisey et al. have
described that an artemisinin dimer exhibits up to 30-fold
more activity than artemisinin in prostate cancer lines [61].
This dimer selectively exerted highly antigrowth potential
and apoptosis in C4-2 (a cell line derived from LNCaP) and
LNCaP cells compared to artemisinin [61]. An enhanced
anticancer activity seems to be given by the stereoisomery of
thelinker[130].Inanotherstudy,C12non-acetaldimersand
one trimer of deoxoartemisinin showed similar potency to
that of the conventional anticancer drugs against many cell
lines. The linker with one amide or one sulfur-centered 2
ethylene groups was essential for potent anticancer activity
[133]. Diastomeric-cholic-acid-derived 1,2,4,5-tetraoxanes
were also tested and found to have high anticancer activity
against human melanoma (Fem X), and cervix cancer
(HeLa) [134] cis stereoisomers were twofold more active.
The authors further suggested that an amide terminus in the
linker confers increased anticancer activity.
Interestingly, Beckman et al. showed that the stereoche-
mistry of the ether linkage of the dimers, of dihydroartemi-
sinin (diDHA), and dihydrodeoxyartemisinin (the respective
endoperoxide lacking dimer) was as important for anti-
tumor activity as the endoperoxide moiety. Dimers were
tested against 60 cells from 9 diﬀerent cancers showing that
although in general the diDHA was more active than dihy-
drodeoxyartemisinin toward anticancer growth, asymmetri-
caldimersofeitherdiDHAordihydrodeoxyartemisininwere
similarly toxic [26]. The mechanism underlying the anti-
proliferative action of the artemisinin-derived dimers needs
further study.
Recently, a series of potent artemisinin-like derivatives
of easy synthesis and anticancer activity has been identiﬁed.
These endoperoxides exhibit high chemical stability and
greater cytotoxicity than artesunate. These compounds also
exhibit relevant antiangiogenic properties as judged by stud-
ies in a zebraﬁsh model [135].
5.2. Fully Synthetic Artemisinins. It is important to recallthat
some limitations of artemisinins such as short half-life (bet-
w e e n1a n d5h o u r s[ 136, 137]), limited aﬀordability, and
solubility need to be further addressed. Although semisyn-
thetic compounds have partially overcome these issues, they
still rely on the availability of natural precursors. In malaria,
some trioxolanes and ozonides with remarkable improved
pharmacokinetics are under clinical development [138]. Re-
cently, it has been found that synthetic trioxolanes with
enhanced pharmacokinetic properties may exhibit a similar
toxicity than artesunate in Schistosomas [139]. Given that ar-
temisinins may be potentially used as anticancer drugs and
possibly in other parasitic and viral infections, the develop-
ment of novel compounds with enhanced pharmacokinetic
propertiesandtargetedanticanceractionsisalsoparamount.
Although novel semisynthetic artemisinins have shown sub-
stantial antineoplastic activity, there is still limited informa-
tion regarding the cytotoxicity of fully synthetic endoperox-
ides. A series of tetraoxacyclohexanes have been shown to
potentially exhibit anticancer properties. A triol substituted
compoundhasdisplayedprominentantitumoractioninvivo
toward melanoma (LOX IMVI) and ovarian (IGROV1) can-
cer in nanomolar concentrations (LC50 60nM) [140]. Other
authors have synthesized compounds with dual action (anti-
malarial/anticancer eﬀect). These deoxycholic-acid-(DCA-)
—and cholic acid (CA)—derived mixed tetraoxanes are cy-
totoxic at very low concentrations and particularly potent
against melanoma cancer (LOX IMVI, LC50 up to 69nM)
[141].
6.FutureDevelopment of Artemisininsas
Anticancer Drugs
Artemisinins have been recommended and widely used as
antimalarials for several years [142]. This drug class has
shown many biological activities, in particular, strong anti-
cancer growth activity. Supporting evidence indicates that
artemisinin-likecompoundsmaybeatherapeuticalternative
inhighlymetastaticandaggressivecancers[44]withnolong-
term eﬀective therapy [44, 61] and commonly developingJournal of Biomedicine and Biotechnology 13
drug resistance [94]. Furthermore, antimalarial endoperox-
ides may act synergistically with other anticancer drugs with
no additional side eﬀects [143].
6.1. What Do We Need to Know? The ability of artemisinins
tokillcancercellsthroughmultipleandheterogeneousmole-
culareventshasbeenwelldocumented.However,someques-
tions about the molecular base of artemisinin-induced cell
death need further study. Growing research has been focus-
ing on determination of the mechanism of bioactivation and
molecular events underlying the artemisinin eﬀects. How-
ever, how the antitumor activity is exerted following arte-
misinin activation is still not well understood. So far, the
precise molecular events involved in how, when, and where
ROS production is initially triggered in cancer cells remain
to be deﬁned. In addition, the relevance of any ROS- in-
dependent mechanism should be also addressed; these might
not be obvious but possibly important for artemisinin
cytotoxicity in some cancer cells. Some other aspects such
as the direct DNA damage induced by artemisinin-like
compounds and the role of p53 status in genotoxicity need
to be further analysed.
One relevant aim in anticancer therapy is cotargeting
multiple pathways minimizing shifting cell hallmarks and
side eﬀects.Whereas it remains important to characterize the
anticancer eﬀects of existing and novel artemisinins deriva-
tives, research also needs to be focused on unveiling the me-
chanismsofcytotoxicitybyidentifyingtheirrelationtoapar-
ticularcancerbiomarkersandmolecules.Artemisininsseems
to regulate key players participating in multiple pathways
such as NF-κB, survivin, NOXA, HIF-1α, and BMI-1. These
molecules and others are to be revealed, which in turn may
be involved in drug response, drug interactions, mechanisms
of resistance, and collateral eﬀects in normal cells. A better
understanding of common mechanisms under similar con-
ditions in diﬀerent cell systems will greatly aid the develop-
ment of targeted artemisinin derivatives. This will improve
artemisinins cytotoxicitybylowering IC50,emergingofresis-
tance, drug associated toxicity, and potentiating drug inter-
actions.
It is important to connect the molecular interactions and
the regulatory eﬀects of artemisinin on the cancer hallmarks
and particularly in those tumors with poor prognosis. Some
cancer cell biomarkers may be potentially useful to predict
success on an artemisinin-based treatment in speciﬁc sys-
tems. Furthermore, novel endoperoxide compounds and
combinational therapies can be addressed to target or cotar-
get markers of carcinoma progression and prevent invasive-
ness and metastatic properties in highly recurrent and ag-
gressive tumors or advanced stage cancers.
Although the beneﬁts of artemisinins in the clinical set-
ting have been already assessed, speciﬁc interactions with es-
tablished chemotherapy need to be further dissected in dif-
ferent cancer cells and their phenotypes. This will be crucial
toimplementclinicaltrialsandtreatmentofindividualcases.
In this regard, long-term therapy with artemisinins also re-
quires close monitoring. It is important to note that the
prototype drug, artemisinin, seems to modulate responses
leading to antagonistic interactions with other anticancer
drugs. However, whereas it may be useful to have the proto-
typedrugasacontrolinvitro,itspharmacokineticproperties
may diﬀer from the semisynthetic artemisinins. Therefore,
artemisinin antagonistic reactions and resistance must be
cautiously validated using diﬀerent semisynthetic deriva-
tives. DHA, artesunate, and artemether are the endoperox-
ides currently licensed for therapeutic use. So far, artemether
has been shown to share similar anticancer properties than
DHA and artesunate [144].
Cancer research drives a permanent discovery of new
genes and interactions. The study of how artemisinin drives
tumor control may become even more complex as immuno-
logical hallmarks are also involved in the generation of tu-
mors. Immunological hallmarks in cancer cells include the
ability to induce chronic inﬂammatory response, evasion of
tumor recognition, and ability to induce tolerance [145].
Whether artemisinin may participate in the mechanisms in-
volved in these events has yet to be determined.
Overall, the real potential and beneﬁts of the artemisinin
drug class remain yet to be uncovered. The imminent pos-
sibility of artemisinins being included in the arsenal of anti
cancer drugs has opened the door for challenging research in
this area, one that seems to fulﬁll many expectations.
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